Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylenediamine SCHEMBL31533530 | 0.95 | CYP3A4 (0.85) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL29212841 | 0.93 | CYP3A4 (0.67) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL28867253 | 0.91 | CYP3A4 (0.64) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL28867255 | 0.91 | CYP3A4 (0.64) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL31410773 | 0.91 | CYP3A4 (0.64) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL29212826 | 0.91 | CYP3A4 (0.64) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL28567051 | 0.91 | CYP3A4 (0.77) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL1020179 | 0.88 | CYP3A4 (1.00) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL27895927 | 0.88 | CYP3A4 (1.00) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL18570 | 0.88 | CYP3A4 (1.00) | CYP3A4TSHRLPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
| US-20070210476-A1 | Machinable Resin Molded Product, Material For Forming The Same, And Model Made Of The Same | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1728832-A1 | MOLDING OF RESIN FOR CUTTING OPERATION, MATERIAL FOR FORMATION THEREOF AND MODEL | Sanyo Chemical Industries, Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | CYP3A4 259/4885TSHR 1796/4885LPAR3 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.